Pacira BioSciences, Inc. (PCRX) Market Cap & Valuation Ratios
Pacira BioSciences, Inc. (PCRX) has a market cap of $1.5B, a trailing P/E of 104.1 and a price-to-sales ratio of 1.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PCRXPacira BioSciences, Inc.Follow PCRX — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- 104.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| PCRX | 1.5 | 104.1 | 2.1 | 14.9 | 12.4% | +6% | 3% | 2% |
| PRGO | 2.2 | — | 1.2 | — | 5.4% | -4% | -38% | -24% |
| TRLV | 2.0 | — | 1.7 | — | 9.3% | -4% | -24% | -27% |
| BCRX | 2.0 | — | 2.1 | — | 19.1% | +69% | -33% | — |
| XERS | 1.9 | — | 5.9 | 52.5 | 3.0% | +36% | 11% | 28% |
| ANIP | 1.7 | 15.7 | 2.0 | 8.1 | 10.4% | +31% | 15% | 13% |
| PAHC | 1.6 | 15.9 | 1.5 | 9.1 | 0.6% | +17% | 13% | 14% |
| ETON | 1.4 | — | 13.5 | 68.6 | 1.0% | +81% | 15% | 42% |
| CRON | 1.2 | 16.9 | 2.4 | 36.9 | 4.0% | +37% | -1% | -0.5% |
| AMPH | 1.1 | 14.9 | 1.9 | 8.1 | 14.3% | +1% | 16% | 8% |
| HROW | 1.1 | — | 4.6 | — | 0.5% | +21% | -1.0% | -2% |
| Median of these 10 | 15.8 | 2.0 | 23.0 | 4.7% | +26% | 5% | 8% |
P/E 104.1 vs. a peer median of 15.8; EV/Sales 2.1 vs. 2.0. PCRX's own P/E sits at the 68th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesPRGO and TRLV and BCRX and XERS and ETON and HROW have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Pacira BioSciences, Inc. — questions
- What is Pacira BioSciences, Inc.'s market cap?
- $1.5B.
- What is Pacira BioSciences, Inc.'s P/E ratio?
- 104.1 on trailing twelve-month earnings to 2026-06-30.
- What is Pacira BioSciences, Inc.'s price-to-sales ratio?
- 1.9.
Every figure on this page comes from Pacira BioSciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.